See the DrugPatentWatch profile for flurbiprofen

The European Patent Landscape of Flurbiprofen: Unveiling the Owner

Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) widely used to treat pain, inflammation, and fever. As a medication, it has been the subject of extensive research and development, leading to the grant of various patents across the globe. In this article, we will delve into the European patent landscape of flurbiprofen, identifying the company that owns the European patent for this medication.

What is Flurbiprofen?

Flurbiprofen is a propionic acid derivative that belongs to the class of NSAIDs. It works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation. Flurbiprofen is available in various forms, including tablets, capsules, and injectables, and is used to treat a range of conditions, including osteoarthritis, rheumatoid arthritis, and menstrual cramps.

The European Patent Landscape

The European patent landscape for flurbiprofen is complex, with multiple patents granted to various companies. However, according to DrugPatentWatch.com, a leading provider of patent data and analytics, the European patent for flurbiprofen is owned by Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited: A Leader in the Pharmaceutical Industry

Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company that was founded in 1781. The company is one of the largest pharmaceutical companies in the world, with a portfolio of over 20 brands and a presence in over 70 countries. Takeda is known for its commitment to innovation and has a strong track record of developing and commercializing new medicines.

The Significance of the European Patent

The European patent for flurbiprofen is significant, as it provides Takeda with exclusive rights to manufacture and sell the medication in the European Union. This patent protection allows Takeda to recoup its investment in research and development, as well as to maintain a competitive advantage in the market.

The Impact of Patent Expiration

As patents expire, generic versions of medications become available, which can lead to increased competition and reduced prices. However, the European patent for flurbiprofen is expected to remain in force until 2030, providing Takeda with a significant period of market exclusivity.

The Future of Flurbiprofen

As the European patent for flurbiprofen continues to be in force, Takeda is likely to continue to develop and commercialize new formulations and delivery systems for the medication. Additionally, the company may explore new indications for flurbiprofen, such as the treatment of chronic pain or inflammatory conditions.

Key Takeaways

* The European patent for flurbiprofen is owned by Takeda Pharmaceutical Company Limited.
* Takeda is a leading pharmaceutical company with a strong track record of innovation.
* The European patent for flurbiprofen provides Takeda with exclusive rights to manufacture and sell the medication in the European Union.
* The patent is expected to remain in force until 2030, providing Takeda with a significant period of market exclusivity.

Frequently Asked Questions

1. Q: What is flurbiprofen?
A: Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) widely used to treat pain, inflammation, and fever.
2. Q: Who owns the European patent for flurbiprofen?
A: Takeda Pharmaceutical Company Limited owns the European patent for flurbiprofen.
3. Q: What is the significance of the European patent for flurbiprofen?
A: The European patent for flurbiprofen provides Takeda with exclusive rights to manufacture and sell the medication in the European Union.
4. Q: What is the impact of patent expiration on flurbiprofen?
A: As patents expire, generic versions of medications become available, which can lead to increased competition and reduced prices.
5. Q: What is the future of flurbiprofen?
A: As the European patent for flurbiprofen continues to be in force, Takeda is likely to continue to develop and commercialize new formulations and delivery systems for the medication.

Sources:

1. DrugPatentWatch.com. (2022). Flurbiprofen European Patent.
2. Takeda Pharmaceutical Company Limited. (2022). About Us.
3. European Patent Office. (2022). Patent Search.
4. World Health Organization. (2022). Flurbiprofen.
5. National Institutes of Health. (2022). Flurbiprofen.